SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
4 references·0 citing·20 second hop
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis (2014)Real world costs and cost-effectiveness o…Delivering affordable cancer care in high-income countries (2011)Delivering affordable cancer …Information on Cost-Effectiveness: An Essential Product of a National Comparative Effectiveness Program (2008)Information on Cost-Effective…Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials (2006)Analyses of Cost Data in Econ…Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphoma (2005)Cost utility in the United St…Methods for the economic evaluation of health care programmes (1987)Cost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Assessing the Impact of Drug Use on Hospital Costs (2008)The Value of “Traditional” Reviews in the Era of Systematic Reviewing (2009)The statistical approach in trial-based economic evaluations matters: get your statistics together! (2021)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)Are high drug prices for hematologic malignancies justified? A critical analysis (2015)The price of innovation: new estimates of drug development costs (2003)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Delivery of affordable and equitable cancer care in India (2014)Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity (2014)Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis (2016)The Journal's Policy on Cost-Effectiveness Analyses (1994)Growth and Quality of the Cost–Utility Literature, 1976–2001 (2005)Saying No Isn't NICE — The Travails of Britain's National Institute for Health and Clinical Excellence (2008)The Obama Administration's Options for Health Care Cost Control: Hope Versus Reality (2009)Healthcare Rationing by Proxy (2010)
this work references cited by second hop

References

  • 2011Delivering affordable cancer care in high-income countries720 cited
  • 2008Information on Cost-Effectiveness: An Essential Product of a National Comparative Effectiveness Program108 cited
  • 2006Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials72 cited
  • 2005Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphoma60 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work